Preventing Postpartum Depression With Intranasal Oxytocin

Completed · Phase 2 · Has a placebo group

Conditions studied: Depression, Postpartum, Anxiety

In brief

The purpose of this study is to test a new treatment for preventing childbirth-related mental illness in postpartum mothers. The treatment is aimed at enhancing maternal bonding, reducing postpartum depression (PPD) and anxiety in mothers at risk, and promoting child development. To this end, the investigators will test the clinical utility of intranasal (IN) oxytocin (OXT) administered to mothers during the first postpartum days.

Key facts

Study ID

NCT02505984

Run by

Massachusetts General Hospital

People needed

56

Starts

2016-01-01

Expected to finish

2023-05-01

Last updated by the study team

2025-02-25

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Third-trimester pregnant women being followed at the Massachusetts General Hospital (MGH) Obstetrics Program
• At risk of postpartum depression (PPD)

You may not qualify if…

• Failure to participate in regular prenatal check-ups
• Current diagnosis Diagnostic and Statistical Manual of Mental Disorders (DSM-5) mental disorder pertaining to psychosis or substance abuse
• Suicidality
• Obstetric complication (e.g., preeclampsia, excessive hemorrhaging)
• Use of potentially confounding or interacting medications
• Complicating pediatric medical condition in the newborn

Where it is running

• Massachusetts General Hosptial — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.